Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. [electronic resource]
Producer: 20191125Description: 2371-2378 p. digitalISSN:- 1569-8041
- Administration, Oral
- Aged
- Antineoplastic Agents -- administration & dosage
- Axitinib -- administration & dosage
- Carcinoma, Renal Cell -- mortality
- Chemotherapy, Adjuvant -- methods
- Disease-Free Survival
- Double-Blind Method
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Humans
- Intention to Treat Analysis
- Kidney Neoplasms -- mortality
- Male
- Middle Aged
- Neoplasm Recurrence, Local -- mortality
- Nephrectomy
- Placebos -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.